Progress in rescue therapy of tenofovir disoproxil fumarate for chronic hepatitis B patients with suboptimal virologic response to adefovir dipivoxil
SHAO Jin-man
TANG Xiao-feng
LIU Yan
XU Dong-ping
Abstract：As the common anti-HBV drug, adefovir dipivoxil (ADV) has been recommended for the rescue therapy of lamivudine-resistant and treat-na?ve patients due to its less cost and no cross-resistance to lamivudine, telbivudine and entecavir. However, since ADV has a lower resistance gene barrier and lower clinical dose, patients with suboptimal virologic response to ADV accumulated during long-term antiviral treatment in clinic. Tenofovir disoproxil fumarate (TDF) has been recommended for the rescue therapy of the patients with suboptimal virologic response to ADV. TDF shows unequal efficacy in lamivudine-experienced and ADV-na?ve patients. And some studiesin vitro reported that ADV resistance mutations reduce susceptibility to TDF. Whether TDF treatment can increase or aggravate the risk of nephrotoxicity for ADV-experienced patients should be concerned in clinical practice. This review aims to summarize progresses in rescue therapy of TDF for chronic HBV-infected patients with suboptimal virologic response to ADV, which will provide help for management of drug-resistant HBV infection.
Keywords：hepatitis Btenofovir disoproxil fumarateadefovir dipivoxildrug resistanceantiviral therapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 371-375 )